FirstWord Pharma’s Post

What nature has intricately and expertly designed to inflict harm can be harnessed as a force for good and a remedy for disease. With over 220,000 venomous animal species worldwide, a complex cocktail of natural pharmacologically active components is at our disposal. This is a fascinating and growing field with the potential to advance drug development. That is why Biosynth have a collection of venoms and toxins as part of our catalog of over a million research products. We offer various animal-derived venoms and toxins with potential for biotechnological and pharmacological applications. To find out more about the world of venoms and toxins and their importance in clinical pharmacology and therapeutics, read our blog: https://lnkd.in/eeNV7m5G Visit our venoms and toxins category to see our full range: https://lnkd.in/e47NUTVX #venoms #toxins #pharmacology #therapeutics #biotechnology #drugdevelopment #drugdiscovery #scientificresearch #naturalproducts #peptides #enzymes

The rabbit pyrogen test (RPT) will now finally be removed from the European Pharmacopoeia (Ph.Eur.). From July 1, 2025, all pharmaceutical manufacturers must have established an alternative method to check all their products for pyrogens. The monocyte activation test (MAT) is always recommended, as it detects all types of pyrogens (both endotoxin and non-endotoxin pyrogens). Our NAT-MAT® goes a little further in this respect, as it combines the classic MAT with nucleic acid amplification technology. This has the following advantages: 🎯Reproducible results and good cell supply ability by utilizing a monocytic cell line 🎯Normalisation of pyrogenic load by parallelly measuring the gene expression of a housekeeping gene – more accurate results 🎯No ethical issues regarding donor information since a cell line is used instead of PBMCs 🎯Fast workflow (time-to-result 1 day) 🎯Highly automated workflow 🎯Analysis of results with easy-to-use software Don't wait any longer! Test our NAT-MAT 👉🏻 https://lnkd.in/eJm4pfif Here is the link to the original article European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 👉🏻 https://lnkd.in/eUe3acms #RPT #pyrogentesting #pharma #ATMP #releasetesting #inprocesscontrol

The global #cytosine market finds its extensive applications across various industries. Cytosine, a nucleobase component of #DNA and RNA, finds predominant use in pharmaceuticals for cancer treatment and antiviral drugs. In addition, it serves as a key ingredient in agricultural products, aiding in plant growth and #cropprotection. With its versatile properties, cytosine demonstrates significant potential for further innovation and expansion across diverse sectors. To know more about the study visit, https://lnkd.in/geskxyvk #DBMR #Cytosine #Biotechnology #Pharmaceuticals #Genomics #LifeSciences #DNASequencing #ResearchandDevelopment #Biosciences #BiotechIndustry #DBMRInsights

Check out LUNATIC from Unchained Labs. LUNATIC is the next-gen UV/Vis spectrophotometer that makes quantification of biologics easier than ever. You need only 2 µl of volume and 10 minutes to measure 96 samples in a single run, without diluting them. Take a look at its application for determining nucleic acid concentration. #DNA #biologics #genomics #nucleicacid

🌟 Trivia Time! 🌟 What is the primary challenge in integrating pharmacogenomics into the drug development process? A) The high cost associated with genomic testing. B) The lack of standardized guidelines for interpreting genomic data. C) The difficulty in identifying actionable genetic variants in diverse populations. D) The resistance from pharmaceutical companies to adopt new technologies. 🔍🤔 #Pharmacogenomics #DrugDevelopment #Genetics #Biotech #ScienceTrivia Sciqst, Precise References in Medicine. www.sciqst.com

Before the launch of a first-to-market rare disease therapy, a global pharmaceutical company decided to implement a genetic test result review program to ensure that patients whose healthcare provider submitted a product enrollment form had a genetic report consistent with the genetic indication and contraindication in the prescribing information. Because of the high complexity of the eligibility requirements, the company recognized the need for external genetics expertise to build and support a fully operationalized genetic eligibility verification program. Learn what happened when this company partnered with us to support its commercial launch! https://lnkd.in/gkfURd-W #lifesciences #genetics

GCCL(Global Clinical Central Lab) has introduced ddPCR(Droplet Digital PCR) as the first in the Korean clinical sample analysis industry, expanding our specialized sample analysis services for Cell&Gene Therapy drug development. 🎉 ddPCR is a form of PCR technology that amplifies and quantifies DNA and RNA sequences within numerous micro-droplets. Check out our analysis services with ddPCR below. 🧪 Replication Competent Lentivirus (RCL) analysis 🧪 Replication Competent AAV (RCAAV) analysis 🧪 HEK293 Residual DNA size analysis 🧪 HEK293 Residual DNA Quantification analysis 🧪 CHO Residual DNA Quantification analysis 🧪 E. coli Residual DNA Quantification analysis 🧪 Mycoplasma detection analysis For more detailed information about ddPCR, please refer to the infographic below! #GCCL #ClinicalTrial #CentralLab #SampleAnalysis #ddPCR #CGT #Cell #Gene #Biotech #Innovation #Healthcare #Pharmaceutical #DrugDevelopment #PharmaceuticalIndustry #Biotechnology

✨ BPGbio, Inc.'s E2-based TPD Platform is First-In-Class ✨ While E2s are known to be crucial in the protein degradation pathway, they had long been considered undruggable due to their smooth surface topology which was difficult to bind to.   To overcome the traditional E2 druggability challenge, BPGbio, Inc. designed our ligands to bind a modified form of E2 with a deeper binding pocket, enabling discovery of selective and specific ligands. BPGbio, Inc.’s unique E2-based TPD approach is differentiated from the typical E3-based approach, with several inherent advantages including potentially higher efficacy and potency, broader disease scope, and reduced drug toxicity. TPD is an emerging field of drug development with the potential to advance beyond today’s protein inhibition designs. BPGbio, Inc. very quickly confirmed TPD was possible via their novel E2 approach, opening a brand new white space in disparate therapeutic areas and indications. BPGbio, Inc. is beginning exploration of their E2 TPD Platform starting with several programs in oncology.    Prior to the E2 discovery by BPGbio, Inc.’s NAi Interrogative Biology Platform, no one had focused on developing an E2-based TPD approach, let alone leveraging it into multiple therapeutic programs. The NAi Interrogative Biology Platform truly unlocked a hidden biological insight that will hopefully improve the human condition for all. For more information about BPGbio, Inc.'s Protein Homeostasis Program please visit: https://lnkd.in/ghG8APdR #proteostasis #proteinhomeostasis #E2notE3 #drugdiscovery #ai #NAiInterrogativeBiology #biopharma #techbio #biotech #protac #TPD

What's changing with ICH Q5A(R2) regulatory guidance update, and its impact to biosafety testing and viral clearance? How to adopt to your current QC testing? Have a Question? Speak to our team of experts. The ICH Q5A (R2) revision addressing viral safety of biotechnology products derived from cell lines of human or animal origin was recently published. Link: https://lnkd.in/ga7jBbKG #ICHQ5Arevision2 #regulatory #safety #biotherapeutics #qualitycontrol #biosafetytesting #viralclearance #viralriskmitigationstrategy #viralsafetyassurance #bioprocessing #CMC

Atelerix Data Series WellReady - Part 4 - The Storage and Shipment of Transformed and Transfected Cell Lines. Find out how we were able to preserve mammalian cell lines for 7 days retaining viability in this case study. Want to know more? Download our Data Pack - https://lnkd.in/eK5_TZsb Heard enough - let me buy it already! - https://lnkd.in/efJy7gAa #CellTechnology #CellLines #Biopharmaceuticals #DrugDiscovery